JMIR Publications

ABSTRACT

Background:

Cancer-related pain remains highly prevalent and frequently undertreated despite advances in oncologic therapies and analgesic strategies. Multidisciplinary approaches are recommended to optimize complex cancer pain management and integrate supportive care; however, robust real-world evidence evaluating their measurable clinical and patient-reported impact remains limited. Structured multidisciplinary cancer pain committees may improve pain control, quality of life, and patient experience, but prospective evaluations in routine clinical practice are scarce.

Objective:

The primary objective of this study is to evaluate changes in pain intensity following multidisciplinary evaluation in patients with cancer-related pain. Secondary objectives include assessing changes in quality of life, pain interference, opioid consumption, treatment-related adverse effects, and patient-reported experience measures after implementation of recommendations from a multidisciplinary cancer pain committee.

Methods:

This is a prospective, single-center, observational longitudinal pre–post study conducted in a tertiary university hospital. A total of 68 adult patients with cancer-related pain referred to a multidisciplinary cancer pain management committee will be consecutively included. Clinical and patient-reported data will be collected at baseline (T0, before committee evaluation) and at 60 days after implementation of recommendations (T1). The primary outcome is change in pain intensity measured using the Visual Analog Scale (VAS). Secondary outcomes include pain interference assessed with the Brief Pain Inventory–Short Form (BPI-SF), health-related quality of life measured with the EQ-5D, opioid consumption, treatment-related adverse effects, and patient satisfaction assessed using Likert-scale patient-reported experience measures. Pre–post comparisons will be performed using paired statistical tests (paired t test or Wilcoxon signed-rank test, depending on data distribution). Statistical significance will be set at P<.05.

Results:

Ethics approval was obtained in January 2026. Patient recruitment is expected to begin in 2026. Data collection will continue through 2027, and results are expected to be available in 2027.

Conclusions:

This study will provide prospective real-world evidence on the clinical and patient-reported impact of a structured multidisciplinary cancer pain management committee. The findings may inform optimization of multidisciplinary pain management models and contribute to improving quality of care in oncology settings. Clinical Trial: Not applicable. This study is a prospective observational pre–post study conducted in routine clinical practice and is not a clinical trial.